Audentes Therapeutics, Inc. (NASDAQ:BOLD) was upgraded by research analysts at ValuEngine from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Thursday.
A number of other research firms also recently commented on BOLD. Leerink Swann initiated coverage on Audentes Therapeutics in a research report on Monday, May 1st. They issued an “outperform” rating and a $22.00 target price on the stock. Zacks Investment Research upgraded Audentes Therapeutics from a “sell” rating to a “hold” rating and set a $17.00 target price on the stock in a research report on Wednesday, May 10th. Wedbush restated an “ourperform” rating and issued a $20.00 target price on shares of Audentes Therapeutics in a research report on Monday, May 15th. Finally, Evercore ISI initiated coverage on Audentes Therapeutics in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $23.00 target price on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the stock. Audentes Therapeutics presently has an average rating of “Hold” and an average price target of $22.40.
Shares of Audentes Therapeutics (BOLD) traded up 11.16% on Thursday, hitting $20.72. 1,768,179 shares of the stock traded hands. The firm has a 50 day moving average price of $19.68 and a 200 day moving average price of $16.97. Audentes Therapeutics has a 52-week low of $13.13 and a 52-week high of $22.82. The firm’s market cap is $575.68 million.
Audentes Therapeutics (NASDAQ:BOLD) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.87) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.77) by $0.10. On average, equities analysts forecast that Audentes Therapeutics will post ($3.53) EPS for the current year.
In other Audentes Therapeutics news, CEO Matthew R. Patterson sold 2,850 shares of Audentes Therapeutics stock in a transaction on Wednesday, July 12th. The stock was sold at an average price of $20.00, for a total value of $57,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Matthew R. Patterson sold 15,000 shares of Audentes Therapeutics stock in a transaction on Thursday, July 13th. The shares were sold at an average price of $20.00, for a total value of $300,000.00. The disclosure for this sale can be found here. Insiders sold 32,850 shares of company stock worth $653,700 in the last 90 days. Company insiders own 47.30% of the company’s stock.
A number of large investors have recently bought and sold shares of BOLD. Redmile Group LLC increased its stake in Audentes Therapeutics by 77.8% in the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock worth $27,922,000 after buying an additional 638,780 shares in the last quarter. Jennison Associates LLC increased its stake in Audentes Therapeutics by 182.4% in the second quarter. Jennison Associates LLC now owns 846,273 shares of the biotechnology company’s stock worth $16,189,000 after buying an additional 546,617 shares in the last quarter. Vanguard Group Inc. increased its stake in Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock worth $12,978,000 after buying an additional 383,837 shares in the last quarter. Alliancebernstein L.P. increased its stake in Audentes Therapeutics by 31.5% in the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock worth $12,256,000 after buying an additional 153,617 shares in the last quarter. Finally, State Street Corp increased its stake in Audentes Therapeutics by 231.6% in the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock worth $4,234,000 after buying an additional 154,544 shares in the last quarter. Institutional investors own 59.76% of the company’s stock.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
